The Renal Function Calculator is intended solely for use by licensed healthcare professionals as a verification support tool. It does not replace independent clinical judgment, current prescribing information, institutional protocol, or pharmacy consultation.
Renal Function Calculator
References
Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16(1):31-41. (Cockcroft-Gault CrCl equation)
Devine BJ. Gentamicin therapy. Drug Intell Clin Pharm. 1974;8:650-655. (Ideal body weight formula)
Adjusted body weight (IBW + 0.4 × [actual − IBW]) — conventional dosing-weight correction factor for actual weight >120% of IBW, as used in aminoglycoside/vancomycin dosing literature (e.g. Bauer LA, et al. Am J Hosp Pharm. 1983;40(8):1352-1357).
Du Bois D, Du Bois EF. A formula to estimate the approximate surface area if height and weight be known. Arch Intern Med. 1916;17:863-871. (BSA — DuBois formula)
Mosteller RD. Simplified calculation of body-surface area. N Engl J Med. 1987;317:1098. (BSA — Mosteller formula)
Inker LA, Eneanya ND, Coresh J, et al. New Creatinine- and Cystatin C-Based Equations to Estimate GFR without Race. N Engl J Med. 2021;385:1737-1749. (CKD-EPI 2021 race-free eGFR equation)
U.S. Food and Drug Administration, Center for Drug Evaluation and Research. Pharmacokinetics in Patients with Impaired Renal Function — Study Design, Data Analysis, and Impact on Dosing. Guidance for Industry. March 2024. https://www.fda.gov/media/78573/download (nonbinding guidance to sponsors on renal-impairment studies and labeling: Cockcroft-Gault CrCl, eGFR in mL/min for labeled dosing, and IBW/adjusted weight in obesity)
Centers for Disease Control and Prevention. Adult BMI Categories. https://www.cdc.gov/bmi/adult-calculator/bmi-categories.html (BMI category names and cutoffs; adults 20 and older)
Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group (international). KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int. 2024;105(4S):S117-S314. (GFR category classification, unchanged from the superseded KDIGO 2012 guideline; also Practice Points 4.2.2 and 4.2.4, Section 4.2 "Dose adjustments by level of GFR" — Practice Points 4.2.2–4.2.5 on using eGFR for drug dosing, cystatin C or measured GFR where more accuracy is needed, and the nonindexed eGFR value)
Tool information, sources & feedback
Page content last changed: . This is the date of the most recent change to this page, not a clinical review date.
Clinical review: A complete, dated review of this tool is not recorded here. An interface update does not certify its clinical content.
Population & limitations: Read the selected module’s eligibility, exclusions, and warnings alongside its result. Coverage differs by module; a result alone does not establish eligibility.
Distinguish FDA labeling, guideline-supported practice, original validation studies, and institutional protocols when applying a recommendation. Source dates and limitations belong to each recommendation; no site-wide “verified” status is implied.
Report a clinical or interface problem · Interface release: site-2026-09-24. Reports include tool and release identifiers only; no patient inputs or results are attached.